Poinsettia (300723.SZ) plans to pay 2.1 yuan for 10 shares to be deducted from interest on June 3

Poinsettia (300723.SZ) announced that the company's 2023 equity distribution plans: cash dividends for every 10 shares...

Zhitong FinanceMay 23 09:06

Ping An Securities: The terminal market resumes growth and selects varieties based on space and pattern

Ping An Securities released a research report saying that judging from changes in the scale and pattern of terminal drug use, the industry ushered in restorative growth in the post-pandemic era. Innovative drugs and varieties with high barriers and good patterns are growing faster than the overall growth rate.

Zhitong FinanceMay 21 21:21

Poinsettia (300723.SZ): A wholly-owned subsidiary, the first-class innovative drug APH01727 tablets were accepted for clinical trial registration

Gelonghui, May 14, 丨 Yipinhong (300723.SZ) announced that recently, the drug clinical trial application for APH01727 tablets, a class of innovative drugs independently developed by Guangzhou Yipinhong Pharmaceutical Co., Ltd. (hereinafter referred to as “Yipinhong Pharmaceutical”), a wholly-owned subsidiary of the company, was accepted by the China Drug Administration and received a “Notice of Acceptance”.

Gelonghui FinanceMay 13 22:51

Poinsettia (300723) 2023 Report and 2024Q1 Quarterly Report Review Report: Innovative R&D continues to accelerate long-term development and is worth looking forward to

Incident The company released its 2023 annual report, achieving operating income of 2.503 billion yuan, a year-on-year increase of 9.79%; net profit to mother of 185 million yuan, a year-on-year decrease of 36.49%; net profit after deduction of 120 million yuan

國元證券May 10 18:26

Poinsettia (300723): Traditional business is steady, progressive and continuous development, AR882 R&D continues to embark on a new journey

Event: On April 26, 2024, the company announced 2023/2024Q1 results. In 2023, the company achieved revenue of 2.503 billion yuan (yoy +9.79%) and net profit of 185 million yuan to mother

華安證券May 8 02:21

A-share changes丨Yipinhong's wholly-owned subsidiary obtained an ocaxipine oral suspension registration certificate with an increase of more than 8%

Glonghui, May 6 | Poinsettia (300723.SZ) increased its increase in the afternoon. It now rose 8.18% to 24.6 yuan. The temporary transaction was 140 million yuan, and the latest market value was 11.17 billion yuan. Yipinhong announced this afternoon that its wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical recently obtained a registration certificate for the oral suspension of oxazepine. Oxcarbazepine oral suspension is suitable for treating primary generalized tonic-clonic seizures and partial seizures, with or without secondary generalized seizures. It is suitable for adults and children over 2 years of age, and can be used alone or in combination with other anticonvulsants.

Gelonghui FinanceMay 6 00:17